, HUJI, Faculty of Medicine, Experimental medicine and cancer research
About the company
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a
proprietary drug (NCE) that after a single injection into subcutaneous fat,
converts white adipose tissue (WAT) into thermogenic, brown-like adipose tissue.
Raziel’s prime-candidate, RZL-012, is a first-in-class, currently in clinical development
to treat obesity and related disorders.
Raziel launched its clinical trial in the US at Q4 2015, expecting final data that
include safety and efficacy, by mid of 2016.
We become fat because we do not burn enough calories, yet consume extra
food. Enhanced thermogenesis (=heat production) can correct this imbalance.
Thermogenesis in large animals is different than that of small rodents and Raziel
carefully verified that its drug acts in small and large mammals as well. Raziel’s
novel drug is able to convert energy-storing white-adipose-tissue (WAT) into
energy-burning brown- like adipose tissue, as evident by histological, cellular and
molecular studies. Moreover, the physiological outcome of this tissue-remodelling
is an outstanding local thermogenesis as clearly demonstrated in human-size
pigs. This thermogenesis lasts for several months following a single treatment,
with the ensuing ~30-50% reduction in s.c. fat at the treated site. The molecular
target of Raziel proprietary drug was also identified and is part of Raziel IP.